Breaking Finance News

Array Biopharma (NASDAQ:ARRY) target upped to $9.00, issued a report today by Leerink Partners

Just yesterday Array Biopharma (NASDAQ:ARRY) traded 63.84% higher at $3.65. Array Biopharma’s 50-day moving average is $3.56 and its 200-day moving average is $3.37. The last stock close price is up 77.50% from the 200-day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Trade Volume was up over the average, with 64,656,332 shares of ARRY changing hands over the typical 2,000,060

In a statement issued on 9/26/2016 Leerink Partners bumped up the target of Array Biopharma (NASDAQ:ARRY) from $6.00 to $9.00 reporting a possible upside of 1.47%.

Previously on Monday August 29, 2016, Jefferies & Co released a statement on Array Biopharma (NASDAQ:ARRY) increased the target price from $6.00 to $7.00. At the time, this indicated a possible upside of 1.05%.

Performance Chart

Array Biopharma (NASDAQ:ARRY)

With a total market value of $0, Array Biopharma has 52 week low of $2.38 and a 52 week high of $6.15 .

Also covering Array Biopharma's price target, a total of 7 brokers have issued a report on the company. The average stock price target is $8.14 with 4 analysts rating the company a strong buy, three brokerages rating the stock a buy, 0 firms rating the stock a hold, 0 brokers rating the stock a underperform, and lastly zero firms rating the stock a sell.

More About Array Biopharma (NASDAQ:ARRY)

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *